Sign In
Buy ELLXF
Elixinol Global Earnings Calls
| Release date | Aug 27, 2026 |
| EPS estimate | - |
| EPS actual | - |
| Revenue estimate | - |
| Revenue actual | - |
| Expected change | +/- 106.98% |
| Release date | Feb 27, 2026 |
| EPS estimate | - |
| EPS actual | -$0.0050 |
| Revenue estimate | - |
| Revenue actual | 5.242M |
| Release date | Aug 29, 2025 |
| EPS estimate | - |
| EPS actual | -$0.0091 |
| Revenue estimate | - |
| Revenue actual | 5.022M |
| Release date | May 29, 2025 |
| EPS estimate | - |
| EPS actual | - |
| Revenue estimate | - |
| Revenue actual | - |
Last 4 Quarters for Elixinol Global
Below you can see how ELLXF performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | May 29, 2025 |
| Price on release | $0.0173 |
| EPS estimate | - |
| EPS actual | - |
| Date | Price |
|---|---|
| May 23, 2025 | $0.0055 |
| May 26, 2025 | $0.0055 |
| May 27, 2025 | $0.0200 |
| May 28, 2025 | $0.0173 |
| May 29, 2025 | $0.0173 |
| May 30, 2025 | $0.0173 |
| Jun 02, 2025 | $0.0173 |
| Jun 03, 2025 | $0.0086 |
| Jun 04, 2025 | $0.0086 |
| 4 days before | 214.55% |
| 4 days after | -50.29% |
| On release day | 0% |
| Change in period | 56.36% |
| Release date | Aug 29, 2025 |
| Price on release | $0.0260 |
| EPS estimate | - |
| EPS actual | -$0.0091 |
| Date | Price |
|---|---|
| Aug 25, 2025 | $0.0179 |
| Aug 26, 2025 | $0.0048 |
| Aug 27, 2025 | $0.0048 |
| Aug 28, 2025 | $0.0200 |
| Aug 29, 2025 | $0.0260 |
| Sep 01, 2025 | $0.0260 |
| Sep 02, 2025 | $0.0260 |
| Sep 03, 2025 | $0.0260 |
| Sep 04, 2025 | $0.0260 |
| 4 days before | 45.25% |
| 4 days after | 0% |
| On release day | 0% |
| Change in period | 45.25% |
| Release date | Feb 27, 2026 |
| Price on release | $0.0081 |
| EPS estimate | - |
| EPS actual | -$0.0050 |
| Date | Price |
|---|---|
| Feb 23, 2026 | $0.0081 |
| Feb 24, 2026 | $0.0081 |
| Feb 25, 2026 | $0.0081 |
| Feb 26, 2026 | $0.0081 |
| Feb 27, 2026 | $0.0081 |
| Mar 02, 2026 | $0.0081 |
| Mar 03, 2026 | $0.0081 |
| Mar 04, 2026 | $0.0081 |
| Mar 05, 2026 | $0.0081 |
| 4 days before | 0% |
| 4 days after | 0% |
| On release day | 0% |
| Change in period | 0% |
| Release date | Aug 27, 2026 |
| Price on release | - |
| EPS estimate | - |
| EPS actual | - |
| Date | Price |
|---|---|
| Jul 27, 2026 | $0.0073 |
| Jul 28, 2026 | $0.0073 |
| Jul 29, 2026 | $0.0073 |
| Jul 30, 2026 | $0.0073 |
| Jul 31, 2026 | $0.0073 |
Elixinol Global Earnings Call Transcript Summary of Q4 2025
Elixinol (EXL) reports a stronger finish to FY'25 with Q4 revenue of $4.1m (up 9.5% QoQ) and FY'25 revenue of $15.5m (+3.6% YoY). Management has shifted the mix toward higher-margin channels (e-commerce grew to 38% of revenue from 21% in 2024) and reduced exposure to lower‑margin bulk ingredients, improving gross margins. The company executed SKU rationalisation, a structural ~30% reduction in operating costs versus Q4 FY'24, and delivered slightly positive EBITDA and positive underlying operating cash flow in Q4. Capital was strengthened via a two-tranche $2.5m raise. Strategic focus for FY'26 is: maintain a lower OpEx run rate, invest selectively in high-return growth (notably Healthy Chef D2C and product innovation like Healthy Chef Metabolic Burn and protein waters), leverage vertically integrated hemp capabilities (contracted volumes up for 2026), and pursue value-accretive M&A. The U.S. Elixinol CBD business faces regulatory uncertainty; management is optimizing contribution while monitoring potential buyers and awaiting greater clarity in the coming 2–3 months. Overall, EXL is positioning as a premium wellness platform aiming for scalability, improved profitability and potential market re‑rating.
